超声引导下术中射频消融与手术切除治疗恶性胃肠道间质瘤肝转移
回顾性分析24例胃肠道间质瘤肝转移患者,共治疗76个肝转移灶(47个手术切除、29个术中超声引导射频消融),所有患者术前术后接受伊马替尼标准治疗。射频消融技术成功率100%,中位随访50.7±34.7个月,1、3、5年总生存率分别为100%、94.4%、87.7%,GIST相关生存率分别为100%、94.4%、94.4%,发生2例主要并发症(胆管狭窄和肝脓肿)。作者认为术中射频消融似乎是可行且安全的治疗选择,与手术切除可能互补。
要点
- 术中超声引导射频消融治疗GIST肝转移技术成功率100%,主要并发症为胆管狭窄和肝脓肿各1例。
- 24例患者中3例(12.5%)在完全缓解后16、51、95个月出现新转移。
- 1、3、5年总生存率分别为100%、94.4%、87.7%,GIST相关生存率分别为100%、94.4%、94.4%。
核心结论
- 术中超声引导射频消融似乎是原发GIST肝转移可行且安全的治疗选择,与手术切除可能互补,有助于对无法手术的GIST肝转移获得完全缓解。
研究设计与样本
- 回顾性病历回顾研究,纳入2009年8月至2017年2月24例GIST肝转移患者,其中14例同期行术中射频消融和原发GIST切除、10例因原发GIST切除后肝复发行术中射频消融;共治疗76个肝转移灶(47个手术切除、29个术中射频消融);所有患者术前术后接受伊马替尼标准治疗;评估技术成功率和有效性、总生存和GIST相关生存及并发症。
诊断标准与关键数值
- 术中射频消融技术成功率为100%。
- 完全缓解后新转移发生率为12.5%(3/24例),分别于术后16、51、95个月出现。
- 1年、3年、5年累积总生存率分别为100%、94.4%、87.7%。
- 1年、3年、5年GIST相关生存率分别为100%、94.4%、94.4%。
- 主要并发症2例:胆管狭窄和肝脓肿。
临床应用与阅片要点
- 作者认为术中射频消融似乎是原发GIST肝转移可行且安全的治疗选择。
- 作者认为术中射频消融与手术切除可能互补,有助于对无法手术的GIST肝转移获得完全缓解。
- 所有患者术前术后接受伊马替尼标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the effectiveness, safety, and feasibility of intraoperative radiofrequency ablation (IORFA) under ultrasound guidance for the treatment of liver metastases from gastrointestinal stromal tumors (GISTs).
MATERIALS AND METHODS: From August 2009 to February 2017, 24 patients with liver metastases of GISTs underwent IORFA, 14 underwent concurrent IORFA and primary GIST resection, and 10 underwent IORFA to treat hepatic recurrence after previous primary GIST resection. Seventy-six hepatic metastases were treated, of which 47 were surgically resected and 29 underwent IORFA. All included patients received imatinib therapy as standard treatment before and after IORFA or surgical resection. A retrospective medical record review was conducted, and follow-up data were collected. Technical success and effectiveness, overall and GIST-specific survival, and complications were assessed.
RESULTS: The mean follow-up duration was 50.7 ± 34.7 months. The technical success rate of IORFA was 100%. New metastases developed in three of the 24 patients (12.5%) following a complete response 16, 51, and 95 months after IORFA, respectively. The cumulative one-, three-, and five-year overall survival rates were 100, 94.4, and 87.7%, respectively. The one-, three-, and five-year GIST-related survival rates were 100, 94.4, and 94.4%, respectively. Two major complications (biliary stricture and hepatic abscess) were observed.
CONCLUSION: IORFA appears to be a feasible and safe treatment option for liver metastasis in patients with primary GISTs. In addition, IORFA and surgical resection may be complementary, helping to obtain complete response in cases of otherwise inoperable liver metastases secondary to GISTs.
引用
- Yoon IS, Shin JH, Han K, et al. Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors. Korean J Radiol. 2018. PMID: 29354000. doi:10.3348/kjr.2018.19.1.54
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。